Drug intelligence / Profile preview

TSR-075

Development stage: Preclinical
Lead developer: GSK
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**TSR-075** is a bispecific antibody that targets both **lymphocyte activation gene 3 protein (LAG3)** and **programmed cell death protein 1 (PD-1)**. It functions as an immune checkpoint inhibitor, aiming to enhance anti-tumor immune responses by simultaneously blocking two critical immune checkpoints on T cells. TSR-075 was initially developed by **AnaptysBio** and later by **Tesaro**. The principal therapeutic area for TSR-075 is **neoplasms (cancer)**. As of the latest updates, TSR-075 remains in **preclinical** development and has not entered clinical trials.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on TSR-075.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSR-075.

Explore the full profile